Semanteon Capital Management LP Acquires Shares of 2,056 Medpace Holdings, Inc. (NASDAQ:MEDP)

Semanteon Capital Management LP acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 2,056 shares of the company's stock, valued at approximately $630,000.

Several other large investors also recently added to or reduced their stakes in MEDP. Miller Howard Investments Inc. NY lifted its position in shares of Medpace by 1.3% in the 4th quarter. Miller Howard Investments Inc. NY now owns 3,075 shares of the company's stock worth $943,000 after purchasing an additional 39 shares during the period. Schulhoff & Co. Inc. lifted its position in shares of Medpace by 2.0% in the 3rd quarter. Schulhoff & Co. Inc. now owns 2,250 shares of the company's stock worth $545,000 after purchasing an additional 45 shares during the period. Campbell Newman Asset Management Inc. lifted its position in shares of Medpace by 0.4% in the 4th quarter. Campbell Newman Asset Management Inc. now owns 11,095 shares of the company's stock worth $3,401,000 after purchasing an additional 46 shares during the period. Treasurer of the State of North Carolina lifted its position in shares of Medpace by 0.5% in the 3rd quarter. Treasurer of the State of North Carolina now owns 10,230 shares of the company's stock worth $2,477,000 after purchasing an additional 50 shares during the period. Finally, Sectoral Asset Management Inc. lifted its position in shares of Medpace by 4.9% in the 3rd quarter. Sectoral Asset Management Inc. now owns 1,181 shares of the company's stock worth $286,000 after purchasing an additional 55 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

MEDP has been the subject of several research reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Medpace in a research report on Monday, March 18th. They issued a "hold" rating and a $395.00 price target for the company. Jefferies Financial Group raised shares of Medpace from a "hold" rating to a "buy" rating and upped their price target for the stock from $340.00 to $450.00 in a research report on Tuesday. Robert W. Baird boosted their price objective on shares of Medpace from $446.00 to $454.00 and gave the stock an "outperform" rating in a research note on Wednesday. UBS Group upgraded shares of Medpace from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $282.00 to $452.00 in a research note on Thursday, February 15th. Finally, StockNews.com upgraded shares of Medpace from a "hold" rating to a "buy" rating in a research note on Tuesday. One analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, Medpace presently has a consensus rating of "Moderate Buy" and an average target price of $443.00.

Medpace Price Performance

Medpace stock traded up $6.16 during mid-day trading on Friday, reaching $395.93. 144,670 shares of the company traded hands, compared to its average volume of 250,817. Medpace Holdings, Inc. has a fifty-two week low of $189.30 and a fifty-two week high of $421.00. The company has a market capitalization of $12.27 billion, a price-to-earnings ratio of 39.70, a price-to-earnings-growth ratio of 1.98 and a beta of 1.38. The firm's fifty day moving average is $397.75 and its two-hundred day moving average is $324.12.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The business had revenue of $511.00 million for the quarter, compared to analyst estimates of $512.39 million. During the same quarter in the prior year, the business posted $2.27 EPS. Medpace's revenue for the quarter was up 17.7% compared to the same quarter last year. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 11.23 earnings per share for the current year.

Insider Buying and Selling at Medpace

In other news, major shareholder Medpace Investors, Llc sold 50,000 shares of the company's stock in a transaction on Friday, February 16th. The shares were sold at an average price of $391.75, for a total value of $19,587,500.00. Following the sale, the insider now directly owns 5,539,947 shares of the company's stock, valued at approximately $2,170,274,237.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, VP Susan E. Burwig sold 102 shares of the company's stock in a transaction on Friday, March 15th. The shares were sold at an average price of $403.00, for a total value of $41,106.00. Following the sale, the vice president now directly owns 15,181 shares of the company's stock, valued at approximately $6,117,943. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Medpace Investors, Llc sold 50,000 shares of the company's stock in a transaction on Friday, February 16th. The shares were sold at an average price of $391.75, for a total transaction of $19,587,500.00. Following the completion of the sale, the insider now directly owns 5,539,947 shares in the company, valued at $2,170,274,237.25. The disclosure for this sale can be found here. In the last quarter, insiders have sold 189,340 shares of company stock worth $76,651,647. 20.30% of the stock is owned by corporate insiders.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.